Annual report on remuneration Total remuneration for 2013 audited Value earned Annual from long-term Total Salary Benefits Pension bonus incentive remuneration awards The Committee may, in specific circumstances and in line with stated principles, apply clawback malus as it determines appropriate.
The total remuneration for 2013 for each Executive Director is set out in the table below: Dr Moncef Slaoui, Sir Andrew Witty, Simon Dingemans, Chairman, CEO CFO Global R&D & Vaccines 2013 % of 2012 % of 2013 % of 2012 % of 2013 % of 2012 % of 000 total 000 total 000 total 000 total $000 total $000 total Salary 1,059 1,033 699 682 1,180 1,153 1 Benefits 67 84 65 73 747 447 Total fixed pay 1,126 16% 1,117 25% 764 23% 755 61% 1,927 23% 1,600 24% Pay for performance Annual bonus including the amount deferred 1,875 905 886 343 1,973 1,404 2 Value earned from LTI awards: Matching awards under Deferred 3 Annual Bonus Plan 249 125 n a n a 485 n a Performance Share Plan 3,250 1,780 1,502 n a 3,763 1,690 Total value earned from LTI awards 3,499 1,905 1,502 n a 4,248 1,690 Total pay for performance 5,374 74% 2,810 64% 2,388 73% 343 28% 6,221 74% 3,094 47% 4 Pension 707 10% 459 11% 140 4% 136 11% 266 3% 1,931 29% 5 Total remuneration 7,207 4,386 3,292 1,234 8,414 6,625 Notes: 1 Certain expenses incurred in the normal course of business are considered to be taxable benefits and as such the table above now includes these figures for 2012 restated and 2013.
Further details are provided on page 98.
2 A n analysis of the value of LTIs earned by Sir Andrew Witty, Simon Dingemans and Dr Moncef Slaoui is set out on pages 112 to 114.
3 The performance period for Simon Dingemans first award under the DABP ends on 31 December 2014.
The earliest period for which remuneration will be recorded under the DABP for Simon Dingemans will therefore be the year ending 31 December 2014.
4 Full details of the pensions accrued to date for the Executive Directors in receipt of a pension from GSK are given on page 105.
5 Following due consideration by the Committee, there has been no reduction of outstanding awards or vesting levels malus applied during 2013 in respect of any of the Executive Directors.
The following sections provide details of each element of Total remuneration including how we intend to implement the policy for 2014.
GSK Annual Report 2013 97 Governance & remuneration Directors Remuneration Report Comparator groups for pay and performance Salary The Committee uses two primary pay comparator groups when For 2014, the average salary increase budget for employees other considering executive pay: than Executive Directors will be approximately 2.5% in both the UK and USA.
UK cross-industry Global pharmaceutical The Committee decided to give the Executive Directors salary comparator group comparator group increases in line with those increases.
Sir Andrew Witty, Simon Anglo American France Sanofi Dingemans and Dr Moncef Slaoui each received a AstraZeneca Switzerland Novartis base salary increase of 2.5%.
BG Group Roche Holdings BHP Billiton UK AstraZeneca The table below sets out the base salaries of the Executive Directors BP USA AbbVie over the last two years and for 2014.
British American Tobacco Amgen Diageo Bristol-Myers Squibb Base salary % Reckitt Benckiser Eli Lilly change 2014 2013 2012 Rio Tinto Johnson & Johnson Sir Andrew Witty 2.5% 1,087,300 1,060,800 1,040,000 Royal Dutch Shell Merck & Co Simon Dingemans 2.5% 717,700 700,150 686,400 SAB Miller Pfizer Dr Moncef Slaoui 2.5% $1,211,800 $1,182,200 $1,159,000 Tesco Unilever Benefits audited Vodafone The following table shows a breakdown of the grossed up cash value Amgen and AbbVie are included for remuneration benchmarking, but of the benefits received by the Executive Directors in 2013 and 2012. are not included in the TSR comparator group.
Sir Andrew Simon Dr Moncef From 2013 onwards financial services companies have been removed Witty Dingemans Slaoui as new regulatory regimes on remuneration applied in that sector make $ their pay structures less comparable.
SAB Miller has been added to the 2013 benefits group.
1 Employee benefits 17,338 21,692 156,529 The global pharmaceutical comparator group is also used as the basis 2 Travel 35,960 29,939 82,163 for the TSR comparator group which features in our long-term 3 International assignment 501,229 incentive awards.
4 Other benefits 13,483 13,483 6,652 The primary pay comparator group for each of the Executive Directors Total 2013 benefits 66,781 65,114 746,573 is shown in the table below: 2012 benefits restated $ Primary pay comparator group 1 Employee benefits 20,198 24,636 177,443 UK Global 2 Director cross-industry pharmaceutical Travel 51,835 34,571 121,739 3 Sir Andrew Witty International assignment 140,690 4 Simon Dingemans Other benefits 12,021 13,904 6,930 Dr Moncef Slaoui Total 2012 benefits 84,054 73,111 446,802 1 When reviewing the CEOs remuneration, the Committee also Employee benefits include healthcare, car allowance, personal financial references pay for a group of leading European companies whose advice and life assurance death in service.
2 selection is based on their size and complexity.
Travel expenses include car travel, family, spouse and partner costs associated with accompanying the director on GSK business, which Summary of total package competitive positioning for the CEO are deemed to be taxable benefits on the individual.
3 Dr Moncef Slaoui was seconded to the UK in November 2010 in order Total remuneration benchmarking m to enable him to be closer to the Vaccines business as he assumed operational responsibility for that part of the Group.
The secondment ended on 31 December 2013.
In line with other senior GSK expatriates, 12 he received appropriate assignment expenses, including accommodation, location allowance, relocation specific financial advice and tax equalisation.
4 Other benefits comprise expenses incurred in the ordinary course of 10 business, which are deemed to be taxable benefits on the individual and as such have been included in the table above for 2012 restated and 2013.
No significant changes to the provision of benefits are proposed for 8 2014.
For further details please refer to page 117 of the Policy Report.
6 4 UK cross-industry Global pharmaceutical European cross-industry group group group Lower quartile to median Median to upper quartile Current position Benchmarking includes salary and the expected value of incentives based on the Committees agreed benchmarking methodology.
